Revvity Receives FDA Clearance for Total Testosterone Assay
Revvity, through its subsidiary IDS, has received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay, which complements its existing tests for free testosterone and sex hormone-binding globulin (SHBG). This development provides a comprehensive solution for testosterone-related disorders.
WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company’s FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla